This site uses cookies to bring you the best experience. Find out more
Skip to main content


Find Out The Latest

You can keep in touch with exciting developments for The Oxford Science Park and its occupiers here.

Contact us on if you would like to know more about any of these stories.

You can also keep up to date by following us on Twitter or LinkedIn    

Blue Earth Diagnostics to be Acquired by Global Leader Bracco Imaging

27th June 2019 ‒ Blue Earth Diagnostics to become a subsidiary of Bracco Imaging; retains name and management team ‒ ‒ Acquisition driven by lead product Axumin® (fluciclovine F 18), a novel molecular imaging agent for use with PET imaging to detect recurrent prostate cancer, and a robust pipeline ‒ ‒ Combined business will leverage Bracco’s diagnostic modalities, global competencies, portfolio and financial resources ‒ BURLINGTON, Mass. and... Read more

Oxford Biomedica named as winner of The Oxford Science Park Innovation Award 2019

Leading gene therapy manufacturer recognised as part of Oxfordshire Business Awards Oxford, UK, June 18 2019 – Its work on life-changing treatments for serious diseases has earned Oxford Biomedica, a leading gene and cell therapy group, The Oxford Science Park Innovation Award 2019. Given as part of the Oxfordshire Business Awards, it recognises the company as the sole manufacturer of the gene therapy vector used in the ground-breaking... Read more

Academic entrepreneur Brian Bellhouse celebrated with naming of new building

Turf cutting for the Bellhouse Building to be performed by Lord & Lady Drayson today Oxford, UK, April 24 2019 –  The Oxford Science Park, one of the UK’s leading parks for science and technology companies, is pleased to announce that its newest building is to be named in recognition of the achievements of academic entrepreneur and Magdalen College Fellow Professor Brian Bellhouse. The turf-cutting ceremony for the Bellhouse... Read more

Blue Earth Diagnostics Announces Addition of Axumin® (fluciclovine (18F)) to EAU Guidelines for imaging in patients with biochemical recurrence in Prostate Cancer

Oxford, UK – April 16, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that Axumin (fluciclovine (18F)) has recently been added to the European Association of Urology (EAU) 2019 Clinical Practice Guidelines in Oncology for Prostate Cancer (PCa). The EAU PCa Guidelines assist clinicians in making informed decisions, taking into consideration the scientific data available and individual... Read more

Blue Earth Diagnostics celebrates five year anniversary

Oxford, UK – March 6, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, recently celebrated the company’s five year anniversary. During this time, Blue Earth Diagnostics has delivered five years of innovation and continued growth with a proven track record and depth of expertise in the rapid development and global commercialization of radiopharmaceuticals for cancer management. Blue Earth Diagnostics employs... Read more